Therapy Detail

Therapy Name SG1-1027
Therapy Description

SGI-1027 binds and inhibits DNMT1, DNMT3A, and DNMT3B, which leads to decreased DNA methylation and may result the activation of silenced tumor suppressor genes (PMID: 19417133).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SGI-1027 DNMT inhibitor (Pan) 5 SGI-1027 binds and inhibits DNMT1, DNMT3A, and DNMT3B, which leads to decreased DNA methylation and may result the activation of silenced tumor suppressor genes (PMID: 19417133).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable SG1-1027 Preclinical - Cell culture Actionable In a preclinical study, SGI-1027, inhibited DNA methylation and reactivated silenced tumor suppressor genes, and induced DNMT1 degradation in a variety of cancer cell lines in culture (PMID: 19417133). 19417133
Unknown unknown hepatocellular carcinoma not applicable SG1-1027 Preclinical - Cell culture Actionable In a preclinical study, treatment with SGI-1027 reduced proliferation of a rat hepatoma cell line in culture in culture (PMID: 19417133). 19417133
Clinical Trial Phase Therapies Title Recruitment Status